2022 - Research.com Best Scientist Award
Jeffrey A. Lieberman mainly investigates Schizophrenia, Psychiatry, Psychosis, Internal medicine and Antipsychotic. Jeffrey A. Lieberman works in the field of Schizophrenia, focusing on Clozapine in particular. His Psychiatry research focuses on Pediatrics and how it relates to Tardive dyskinesia.
His study in Psychosis is interdisciplinary in nature, drawing from both First episode, Brain morphometry, Neuroscience and Meta-analysis. His Internal medicine research is multidisciplinary, incorporating elements of Clinical Global Impression, Endocrinology and Brief Psychiatric Rating Scale. His Antipsychotic research also works with subjects such as
Jeffrey A. Lieberman mainly focuses on Schizophrenia, Psychiatry, Internal medicine, Psychosis and Antipsychotic. The Schizophrenia study combines topics in areas such as Genetics and Neuroscience. His research investigates the connection between Psychiatry and topics such as Clinical psychology that intersect with problems in Neurocognitive.
His research in Internal medicine focuses on subjects like Endocrinology, which are connected to Neuroactive steroid. Jeffrey A. Lieberman combines subjects such as First episode, Magnetic resonance imaging and Cognition with his study of Psychosis. In his study, Risperidone, Haloperidol and Anesthesia is strongly linked to Olanzapine, which falls under the umbrella field of Antipsychotic.
His main research concerns Schizophrenia, Psychiatry, Internal medicine, Antipsychotic and Psychosis. His biological study deals with issues like Pharmacology, which deal with fields such as Agonist. Jeffrey A. Lieberman combines subjects such as Psychotherapist and Affect with his study of Psychiatry.
His studies deal with areas such as Placebo, Endocrinology, Oncology and Positive and Negative Syndrome Scale as well as Internal medicine. Jeffrey A. Lieberman works mostly in the field of Antipsychotic, limiting it down to topics relating to Pharmacogenetics and, in certain cases, Allele, as a part of the same area of interest. His work in Psychosis covers topics such as Intervention which are related to areas like Early detection.
His primary areas of study are Schizophrenia, Psychiatry, Antipsychotic, Internal medicine and Psychosis. His Schizophrenia study incorporates themes from Genome-wide association study, Intervention, Magnetic resonance imaging and Functional magnetic resonance imaging, Neuroscience. His study in the field of Cognition, Schizophrenia, Biological psychiatry and Schizotypy is also linked to topics like Suicidal ideation.
He interconnects Genetics, Clozapine, Bioinformatics, Meta-analysis and Pharmacology in the investigation of issues within Antipsychotic. The Internal medicine study combines topics in areas such as Placebo, Linkage disequilibrium, Oncology and Positive and Negative Syndrome Scale. His Psychosis study integrates concerns from other disciplines, such as Logistic regression, Pacific islanders, Affect and Clinical psychology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz.
The New England Journal of Medicine (2005)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke;Stephan Ripke;Benjamin M. Neale;Benjamin M. Neale;Aiden Corvin;James T. R. Walters.
Genome-wide association study identifies five new schizophrenia loci
Stephan Ripke;Alan R. Sanders;Kenneth S. Kendler;Douglas F. Levinson.
Nature Genetics (2011)
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
S. Hong Lee;Stephan Ripke;Stephan Ripke;Benjamin M. Neale;Benjamin M. Neale;Stephen V. Faraone.
Nature Genetics (2013)
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
Delbert Robinson;Margaret G. Woerner;Jose Ma. J. Alvir;Robert Bilder.
Archives of General Psychiatry (1999)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph Patrick McEvoy;Jonathan M. Meyer;Donald C. Goff;Henry A. Nasrallah.
Schizophrenia Research (2005)
Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis
Diana O. Perkins;Hongbin Gu;Kalina Boteva;Jeffrey A. Lieberman.
American Journal of Psychiatry (2005)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider;Pierre N. Tariot;Karen S. Dagerman;Sonia M. Davis.
The New England Journal of Medicine (2006)
Duration of psychosis and outcome in first-episode schizophrenia.
Antony D. Loebel;Jeffrey A. Lieberman;Jose M. Alvir;David I. Mayerhoff.
American Journal of Psychiatry (1992)
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: